About C4X Discovery
C4X Discovery is a publicly listed company based in Manchester (United Kingdom) founded in 2008. Developer of optimized drug discovery and design services. The company has 46 employees. C4X Discovery has completed 1 acquisition, including Adorial. C4X Discovery offers products and services including Conformetrix Platform and PatientSeek Platform. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is C4X DISCOVERY HOLDINGS PLC.
Company details
Founded in 2008 and based in Manchester, United Kingdom, operations focus on the biotechnology sector through drug discovery and design. Proprietary software platforms, including Taxonomy3 for human genetics analysis and Conformetrix for determining 3D molecular shapes, are utilized alongside NMR technology for candidate optimization. A pipeline includes treatments for addiction, diabetes, inflammation, and oncology.
- Headquarters Manchester, United Kingdom
- Employees 46
- Stage Public
- SectorsHealthcare
- Website c4xdiscovery.com
- Social LinkedIn X
- Legal Name C4x Discovery Holdings Plc
- Date of Incorporation 16 Jul, 2014
- Jurisdiction MANCHESTER
Products & Services of C4X Discovery
C4X Discovery offers a comprehensive portfolio of products and services, including Conformetrix Platform and PatientSeek Platform.
Enables rational drug design with 4D structural data for immuno-inflammatory treatments.
Provides genetics-led insights for patient response prediction in therapies.
Funding Insights of C4X Discovery
- Total Rounds 9
- Last Round Post-IPO — $11M
- Investors Count 7
All 9 funding rounds of C4X Discovery with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $11M | Post-IPO | – | – | |
| Aug 2022 | $6.93M | Post-IPO | – | – | |
| Oct 2020 | $914,893 | Post-IPO | – | – | |
| Oct 2019 | Post-IPO | – | – | ||
| Sep 2016 | $6.65M | Post-IPO | – | – | |
| Mar 2015 | Grant | – | – | ||
| Oct 2014 | $17.69M | Post-IPO | – | – | – |
| Jul 2014 | Grant | – | – | ||
| Nov 2009 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in C4X Discovery
C4X Discovery has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Astrazeneca and Calculus Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed across multiple sectors. | 2001 | polarcapitalfunds.com | London, United Kingdom | |
Adams Plc is focused on special situation investment opportunities. | adamsplc.co.uk | Douglas, United Kingdom | ||
UK venture capital investments are managed by Calculus Capital. | 1999 | calculuscapital.com | London, United Kingdom | |
Life Science focused VC firm investing in the US & UK | aquariusequity.com | Manchester, United Kingdom | ||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom | |
Investment banking services are provided to lower and mid-market companies. | 1876 | panmure.com | London, United Kingdom | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom |
Investor details for C4X Discovery
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of C4X Discovery
19 people are tracked at C4X Discovery (9 in leadership, 5 in board & advisors, 5 in team); the tracked headcount is 46.
| Name | Role | Group |
|---|---|---|
Simon Jones | Head Of IT | Leadership |
Neil Humphryes-Kirilov | Associate Director Of Human Genomics | Leadership |
Brad Hoy | CFO | Leadership |
Clive Dix | CEO | Leadership |
Catherine Tralau-Stewart | Chief Scientific Officer | Leadership |
Emma Blaney | COO | Leadership |
Nick Ray | Chief Scientific Officer | Leadership |
Martin Watson | VP Structural Analysis | Leadership |
Ana Sousa Manso | Associate Director Of Project And Portfolio Managment | Leadership |
Natalie Walter | Non-Executive Director | Board & advisors |
Alex Stevenson | Non-Executive Director | Board & advisors |
Simon Harford | Non-Executive Director, Board member | Board & advisors |
Mario Polywka | Non-Executive Director, Board member | Board & advisors |
Harry Finch | Non-Executive Director | Board & advisors |
Shilina Roman | SVP Drug Discovery | Team |
Martin Connolly | Principal Scientist | Team |
Michael Beaumont | Principal Structural Analyst | Team |
Lyrelle Lloyd | Scientific Operations Manager | Team |
Matthew Smith | Office Manager | Team |
Complete people profiles for C4X Discovery
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by C4X Discovery
C4X Discovery has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Adorial.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proprietary in silico genomics platform is utilized for drug discovery. | adorial.com | High Wycombe, United Kingdom | 2014 | Mar 2016 | $2.36M |
Complete acquisition details for C4X Discovery
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of C4X Discovery
5 dated milestones of C4X Discovery across 16 years, from founding to its latest funding, stage changes and deals.
- Founded C4X Discovery is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Adorial.
- Funding Latest funding round, Post-IPO, of $11.0M.
Web traffic of C4X Discovery
The website of C4X Discovery (c4xdiscovery.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▼ 7.5% vs previous month
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as C4X Discovery (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about C4x Discovery
Complete news archive for C4X Discovery
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C4X Discovery
C4X Discovery was founded in 2008 and raised its 1st funding round 1 year after it was founded.
C4X Discovery is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
C4X Discovery has 46 employees.
Annual revenue of C4X Discovery is $7.65M as on Jul 31, 2021.
Founded in 2008 and based in Manchester, United Kingdom, operations focus on the biotechnology sector through drug discovery and design. Proprietary software platforms, including Taxonomy3 for human genetics analysis and Conformetrix for determining 3D molecular shapes, are utilized alongside NMR technology for candidate optimization. A pipeline includes treatments for addiction, diabetes, inflammation, and oncology.
C4X Discovery offers Conformetrix Platform and PatientSeek Platform.
C4X Discovery has made 1 acquisition, including Adorial.
C4X Discovery has 7 investors. Key investors include Gov.uk, Astrazeneca, Calculus Capital, Polar Capital, and Panmure Gordon.
C4X Discovery operates through C4x Discovery Holdings Plc.